Kindred Biosciences (Nasdaq: KIN) reported disappointing results from a study of CereKin to treat dogs with osteoarthritis sending the stock price plummeting $4.00 to close at $10.21.
Disappointing study results for Kindred Biosciences
August 21, 2014 at 16:25 PM EDT